AbbVie Completes Acquisition of Landos Biopharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)
May 24, 2024 8:31 AM EDTDeutsche Bank analyst James Shin reiterated a Hold rating and $175.00 price target on Abbvie (NYSE: ABBV).
The analyst comments "IMS/IQVIA data for the week ending 5/17/24 show branded Humira with 72.2% share (+0.4% w/w) of Adalimumab scripts. Co-branded Humira (Cordavis x ABBV) captured 9.7% share (+0.2% w/w) of Adalimumab scripts. On a combined basis (branded +... More
